Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharming Group N.V.

http://www.pharming.com

Latest From Pharming Group N.V.

Coronavirus Notebook: Moderna’s New Boosters More Effective Against Omicron BA.4/BA.5, Inotrem Reports Good Results For Nangibotide In Severe COVID-19

The European Medicines Agency has recommended updating the vaccine product information to include heavy menstrual bleeding with both Spikevax and Comirnaty, and urticaria with Spikevax. The World Health Organization says that the Omicron BA.5 strain and all its descendent lineages continue to be dominant at global level.

Europe International

After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?

Industry investors foresee continued hardship for public companies still without compelling clinical data for their assets, plus the growing influence of the US Inflation Reduction Act on biopharma strategy.

Companies Commercial

Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone

Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates. 

Financing Business Strategies

Vaxcyte’s 24-Valent Pneumococcal Vaccine Shows Best-In-Class Potential

The biotech’s share price jumps more than two-thirds as analysts hail top-line Phase I/II data as better than expected. Vaxcyte hopes to hold Phase III planning discussions with the FDA in 2023.

Vaccines Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Synthesis Technologies, Production Processes
    • Transgenics
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register